StockNews.AI
ACET
StockNews.AI
113 days

Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

1. Adicet Bio's abstract accepted for oral presentation at ASGCT 2025. 2. Presentation focuses on ADI-270, a therapy for autoimmune diseases and cancer.

2m saved
Insight
Article

FAQ

Why Bullish?

The acceptance for oral presentation indicates momentum in clinical development. Historical examples show positive investor reaction to similar announcements.

How important is it?

The presentation is a key milestone that can validate ACET's research efforts and attract funding.

Why Long Term?

Presentations at conferences can enhance visibility and attract investors over time, similar to past oncology advancements.

Related Companies

BMYJNJABBV
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of an abstract for an oral presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place May 13-17, 2025, in New Orleans, LA. Details of the oral presentation are as follows: Title: ADI-270, an Armo.

Related News